Original Research

DOI: 10.4244/EIJ-D-23-00628

Vulnerable plaque features and adverse events in patients with diabetes mellitus: a post hoc analysis of the COMBINE OCT-FFR trial

David del Val1,2, MD, PhD; Balazs Berta3,4, MD, PhD; Tomasz Roleder5,6, MD, PhD; Krzysztof Malinowski7, MSc; Teresa Bastante1,2, MD; Renicus S. Hermanides4, MD, PhD; Wojciech Wojakowski5, MD, PhD; Enrico Fabris8, MD, PhD; Javier Cuesta1,2, MD, PhD; Giuseppe De Luca9,10, MD, PhD; Fernando Rivero1,2, MD, PhD; Fernando Alfonso1,2, MD, PhD; Elvin Kedhi5,11, MD, PhD

Abstract

BACKGROUND: Thin-cap fibroatheroma (TCFA) lesions are associated with a high risk of future major adverse cardiovascular events. However, the impact of other optical coherence tomography-detected vulnerability features (OCT-VFs) and their interplay with TCFA in predicting adverse events remains unknown.

AIMS: We aimed to evaluate the individual as well as the combined prognostic impact of OCT-VFs in predicting the incidence of the lesion-oriented composite endpoint (LOCE) in non-ischaemic lesions in patients with diabetes mellitus (DM).

METHODS: COMBINE OCT-FFR (ClinicalTrials.gov: NCT02989740) was a prospective, double-blind, international, natural history study that included DM patients with ≥1 non-culprit lesions with a fractional flow reserve>0.80 undergoing systematic OCT assessment. OCT-VFs included the following: TCFA, reduced minimal lumen area (r-MLA), healed plaque (HP), and complicated plaque (CP). The primary endpoint, LOCE − a composite of cardiac mortality, target vessel myocardial infarction, or clinically driven target lesion revascularisation up to 5 years − was analysed according to the presence of these OCT-VFs, both individually and in combination.

RESULTS: TCFA, r-MLA, HP and CP were identified in 98 (25.3%), 190 (49.0%), 87 (22.4%), and 116 (29.9%) patients, respectively. The primary endpoint rate increased progressively from 6.3% to 55.6% (hazard ratio 15.2, 95% confidence interval: 4.53-51.0; p<0.001) in patients without OCT-VFs as compared to patients with concomitant HP, r-MLA, CP, and TCFA. The coexistence of TCFA with other OCT-VFs resulted in an increased risk of the LOCE at 5 years.

CONCLUSIONS: In DM patients with non-ischaemic lesions, TCFA was the strongest predictor of future LOCE events. However, lesions that present additional OCT-VFs are associated with a higher risk of adverse events than OCT-detected TCFA alone. Further randomised studies are warranted to confirm these findings and their potential clinical implications.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 11
Jun 3, 2024
Volume 20 Number 11
View full issue


Key metrics

Suggested by Cory

Clinical research

10.4244/EIJ-D-22-00306 Feb 6, 2023
Long-term outcomes of patients with normal fractional flow reserve and thin-cap fibroatheroma
Fabris E et al
free

Clinical research

10.4244/EIJ-D-22-00562 Jan 23, 2023
Outcomes of non-ischaemic coronary lesions with high-risk plaque characteristics on coronary CT angiography
Yang S et al
free

Editorial

10.4244/EIJ-E-23-00055 Dec 18, 2023
Pullback pressure gradient index: can it predict plaque phenotype?
Bourantas C and Yap N
free

10.4244/EIJV16I7A99 Sep 18, 2020
Functional assessment 3.0: from wire through angio to OCT
Campo G and Biscaglia S
free
Trending articles
153.65

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
54.9

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
43.75

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved